- Market Size (2026)
- USD 91.9 Bn
- Forecast (2036)
- USD 149.7 Bn
- CAGR (2026 to 2036)
- 5.0%
How big is Pharmaceutical Secondary Packaging Market in 2026?
Global pharmaceutical secondary packaging market value is projected to climb from USD 87.5 billion in 2025 to USD 91.9 billion in 2026, advancing at an anticipated 5.0% CAGR to reach USD 149.7 billion by 2036.
On May 27, 2025, the U.S. Food and Drug Administration ended its stabilization grace period under the Drug Supply Chain Security Act and required pharmaceutical trading partners to exchange package-level electronic EPCIS verification data [1]. Every prescription pack leaving a filling line must carry a readable 2D barcode and tamper-evident seal around the primary vial or blister, due to which drug makers rely heavily on regulated pharmaceutical packaging systems. According to FMI, the global pharmaceutical secondary packaging market value moved from USD 87.5 billion in 2025 to USD 91.9 billion in 2026 and is forecast to reach USD 149.7 billion by 2036 on a 5.0% CAGR, adding USD 57.8 billion in annual market size. Serialized Folding Cartons & Wallet Packs are projected to capture 32.9% of secondary format market value in 2026 because flat board blanks run cleanly on high-speed laser coders, although frequent artwork changes still slow down short batch runs.
Key Market Trends & Insights
- By secondary format: Serialized Folding Cartons & Wallet Packs are projected to capture 32.9% of 2026 market size because flat panels provide scannable surfaces for 2D DataMatrix codes and patient dosing calendars.
- By material: Solid Bleached & Recycled Paperboard is estimated to command 77.9% of 2026 category valuation as high-whiteness clay coatings deliver crisp UV-ink contrast on 400-carton-per-minute lines.
- By therapeutic class: Oral Solid Dose Blister & Bottle Cartons are expected to concentrate 55.7% of 2026 market value because chronic tablet prescriptions require protective outer cartons that retain folded outserts.
- By anti-counterfeiting & traceability: 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals are forecast to account for 46.3% of 2026 segment valuation owing to statutory unit-level verification rules across North America and Europe.
- By cold-chain compatibility: Ambient Controlled Room Temperature is anticipated to hold 58.3% of 2026 industry valuation through high-volume distribution of oral tablets and room-stable capsules.
Regional Highlights
- Top national expansion: Brazil is projected to lead major pharmaceutical converting markets at a 5.9% CAGR through 2036 under ANVISA generic drug packaging and serialization expansion.
- Broader country progression: South Korea is expected to expand at a 5.7% CAGR ahead of the USA at 4.6% and Germany at 4.3%, while Switzerland is forecast to advance at a 4.2% yearly pace.
Market Size & Forecast
Table 1: Market Size and Forecast for the Pharmaceutical Secondary Packaging Market (USD billion and CAGR percentage), 2025 to 2036
| Metric | Value |
|---|---|
| 2025 Market Size | USD 87.5 billion |
| Estimated Market Size in 2026 | USD 91.9 billion |
| Projected Market Size by 2036 | USD 149.7 billion |
| CAGR, 2026 to 2036 | 5.0% |
| Added Market Value, 2026 to 2036 | USD 57.8 billion |
Selection of secondary packaging formats depends upon national anti-tampering rules and the number of batch changes completed during one production shift. Under European Medicines Agency oversight of Directive 2011/62/EU and Commission Delegated Regulation (EU) 2016/161, prescription medicine cartons must carry both a unique 2D barcode identifier uploaded to the European repository and a physical anti-tampering device checked before dispensing [2]. Plain tuck-flap boxes cannot meet this requirement without an outer seal. As a result, drug packagers are moving toward glued carton flaps and tamper-evident security labels so that pharmacists can spot any opened pack right away.
Converted Pack Volume and Serialization Line Sizing
Table 2: Converted Pack Volume and Serialization Line Sizing for the Pharmaceutical Secondary Packaging Market (USD billion and operational ranges), 2025 to 2036
| Metric | 2025 | 2026 | 2036 |
|---|---|---|---|
| Market size (USD billion) | 87.5 | 91.9 | 149.7 |
| Converted secondary pharma units (billion packs) | 172.0 to 184.0 | 179.0 to 192.0 | 268.0 to 289.0 |
| GS1-serialized unit share (%) | 76.0% to 80.0% | 79.0% to 83.0% | 91.0% to 95.0% |
| Average realized secondary pack value (USD) | 0.48 to 0.51 | 0.49 to 0.52 | 0.52 to 0.56 |
Operational note: Converted pack volumes cover commercial folding cartons and wallet packs as well as parenteral vial trays and multi-layer prescription labels across global pharmaceutical finishing lines.
Smaller biologic batches and new autoinjector pens require packaging lines that can switch jobs quickly without misprinting lot numbers. In May 2026, Korber AG presented its SPE6-P2 Stickpack Line and ALVA automated inspection system at interpack in Dusseldorf to link primary filling directly with secondary P2 cartoning for smaller production runs [3]. Direct camera checks connected with blister packaging systems also help plants avoid batch quarantine delays when shipments cross international borders.
Per Capita & Finishing Facility Sizing
Table 3: Per Capita and Facility Valuation Indicators for the Pharmaceutical Secondary Packaging Market (USD), 2025 to 2036
| Metric | 2025 | 2026 | 2036 |
|---|---|---|---|
| World population (billion) | 8.2 | 8.3 | 9.0 |
| Market value per capita (USD) | 10.6 | 11.1 | 16.7 |
| Market value per 1,000 people (USD) | 10,630 | 11,072 | 16,726 |
| Annual market value per GMP packaging site (USD million) | 17.5 to 19.8 | 18.4 to 20.8 | 28.5 to 32.4 |
Table 4: Pharmaceutical Plant & Segment Valuation Indicators (USD and percentages), 2026
| Metric | Value | Institutional Reference Basis |
|---|---|---|
| Market size, 2026 | USD 91.9 billion | 2026 global market value baseline |
| GMP pharmaceutical packaging sites worldwide | 4,750 facilities | Global FDA / EMA / WHO registered site base |
| Solid bleached & recycled paperboard market value, 2026 | USD 71.6 billion | 77.9% material segment allocation |
| Oral solid dose blister & bottle carton market value, 2026 | USD 51.2 billion | 55.7% therapeutic class allocation |
Biologic vials and prefilled pens stored between 2 degrees Celsius and 8 degrees Celsius need outer cartons that do not bow or soften when condensation forms. Drug logistics teams therefore combine wet-strength folding boxes with pharmaceutical cold-chain packaging shippers so that fragile glass barrels stay protected during air freight.
Analyst Perspective
"Mandatory unit-level EPCIS verification and GLP-1 autoinjector launches are shifting drug makers toward fiber-based protective trays and RFID labels. Stringent stability filings and zero-defect vision tolerances still lengthen converter qualification cycles across regulated plants."
- Nandini Roy Choudhury, Principal Consultant, Future Market Insights.
How is the pharmaceutical secondary packaging market segmented?
The pharmaceutical secondary packaging market is segmented by secondary format, material, therapeutic class, anti-counterfeiting & traceability, cold-chain compatibility, and region. In 2026, Serialized Folding Cartons & Wallet Packs is projected at 32.9%, Solid Bleached & Recycled Paperboard at 77.9%, Oral Solid Dose Blister & Bottle Cartons at 55.7%, 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals at 46.3%, and Ambient Controlled Room Temperature at 58.3%.
By secondary format: Serialized Folding Cartons & Wallet Packs, Tamper-Evident Labels, Inserts & Outserts, Injector & Vial Protective Trays, and Shrink-Wrapped Multipack Bundles.
By material: Solid Bleached & Recycled Paperboard and Thermoformed rPET/PP & Barrier Films.
By therapeutic class: Oral Solid Dose Blister & Bottle Cartons and Parenteral Biologics, Pens & Prefilled Syringes.
By anti-counterfeiting & traceability: 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals, RFID / NFC Smart Unit-Level Tagging, and Holographic Foil, Microtext & Overt Ink.
By cold-chain compatibility: Ambient Controlled Room Temperature and Freeze-Thaw & 2°C to 8°C Wet-Strength Board.
Why do Serialized Folding Cartons & Wallet Packs lead the secondary format category?
Serialized Folding Cartons & Wallet Packs are projected to capture 32.9% of secondary format valuation in 2026, supported by high-speed cartoning.
Table 5: Secondary Format Share for the Pharmaceutical Secondary Packaging Market (percentage share), 2026
| Secondary Format | Share (2026) |
|---|---|
| Serialized Folding Cartons & Wallet Packs | 32.9% |
| Other Segments Combined | 67.1%* |
| Total | 100.0% |
*Note: Combined share of remaining secondary format categories totaling 100.0% of 2026 market size.
Table 6: Secondary Format Leadership and Market Growth for the Pharmaceutical Secondary Packaging Market (segment and CAGR percentage), 2026 to 2036
| Metric | Value |
|---|---|
| Global CAGR (2026 to 2036) | 5.0% |
| Leading Segment | Serialized Folding Cartons & Wallet Packs |
Pharmaceutical finishing plants rely on pre-glued paperboard cartons and heat-sealed wallet packs because flat blanks feed into horizontal cartoners at 300 to 500 packs per minute while leaving six flat panels for dosage text and Braille dots. Wallet packs also help patients follow daily tablet schedules by printing calendar instructions around sliding blister card assemblies. When converters pre-insert the folded patient leaflet inside the carton sleeve at the printing plant, contract packagers can skip a separate leaflet-feeding step on the filling line.
- Serialized Folding Cartons & Wallet Packs are projected to secure 32.9% of secondary format market value in 2026 by combining rapid mechanical erection with verified Braille and barcode legibility.
- In April 2026, Faller Packaging GmbH & Co. KG highlighted its 2-in-1 Combi Pack that pre-assembles the folding carton and leaflet into a single unit to lower day-to-day pharmaceutical packaging line costs [4].
Why does Solid Bleached & Recycled Paperboard define the largest material segment?
Solid Bleached & Recycled Paperboard is estimated to secure 77.9% of the material category in 2026, driven by optical print contrast.
Paperboard mills supply solid bleached sulfate and bright recycled cartonboard that fold cleanly on cartoning lines without cracking along the score lines. The smooth clay-coated surface also gives inline cameras a sharp contrast when grading UV-laser DataMatrix codes to ISO/IEC 15415 Grade A standards. Under European Union Regulation (EU) 2025/40, drug makers are replacing thermoformed plastic vial cradles with die-cut paperboard inserts and medical device secondary cartons so that empty packs can go directly into household paper recycling without plastic separation fees.
- Solid Bleached & Recycled Paperboard is estimated to command 77.9% of the material segment valuation in 2026 as drug makers substitute plastic blister trays with mono-material fiberboard.
- In March 2025, Stora Enso Oyj commenced commercial operations on its EUR 1 billion consumer packaging board line in Oulu, Finland with 750,000 tonnes of annual folding boxboard and kraft capacity [5].
What keeps Oral Solid Dose Blister & Bottle Cartons ahead by therapeutic class?
Oral Solid Dose Blister & Bottle Cartons are expected to command 55.7% of therapeutic class valuation in 2026, reflecting tablet prescription volume.
Daily prescriptions for heart and metabolic conditions create steady demand for blister cards and plastic tablet bottles that need an outer carton to block light and hold the patient leaflet. Injectable pens and biologics carry a higher price per pack, whereas oral tablets use a much larger share of total cartonboard tonnage as well as sterile medical packaging trays across retail and mail-order pharmacies. Due to this recurring prescription volume, oral solid dosage lines remain the core buyer of printed pharmaceutical cartons.
- Oral Solid Dose Blister & Bottle Cartons are expected to hold 55.7% of therapeutic class market value in 2026 because retail pharmacy dispensing relies on standardized unit-of-sale cartons.
- In November 2025, Smurfit Westrock plc unveiled a dedicated clinical pharmaceutical packaging facility engineered to supply serialized cartons and thermoformed assembly kits for drug trials [6].
Why does 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals lead traceability demand?
2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals are forecast to account for 46.3% of traceability valuation in 2026, owing to statutory mandates.
Track-and-trace laws in North America and the European Union as well as Brazil and South Korea require every prescription carton to carry a 2D DataMatrix barcode showing the product number and batch code with an expiry date. Drug plants can meet these rules at a low cost per pack by combining inline laser marking with fiber-tearing hot-melt glue or perforated seals instead of adding costly authentication transponders to basic generic tablets. Because of this cost advantage, printed 2D codes and tamper seals hold the largest share of traceability valuation.
- 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals are forecast to represent 46.3% of traceability market value in 2026 as wholesalers enforce real-time electronic barcode verification.
- In May 2026, Schreiner MediPharm and HERMA demonstrated process-reliable shielded RFID-Labels on the HERMA 132M HC wrap-around labeling machine at interpack with near-zero chip breakage [7].
What gives Ambient Controlled Room Temperature the leading position in cold-chain compatibility?
Ambient Controlled Room Temperature formats are anticipated to hold 58.3% of cold-chain compatibility market size in 2026, reinforced by oral drug stability.
Oral tablets and skin-care tubes stored at 15 degrees Celsius to 25 degrees Celsius controlled room temperature do not need special wet-strength resins or water-repellent coatings on their outer cartons. Standard clay-coated folding boxboard runs smoothly on die-cutters and folder-gluers for these dry-storage medicines, whereas refrigerated biologic lines must specify temperature-controlled pharmaceutical packaging solutions so that damp cold-room air does not warp the carton.
- Ambient Controlled Room Temperature is anticipated to capture 58.3% of cold-chain compatibility market value in 2026 because room-stable oral medications anchor global prescription volume.
- In September 2026, Schreiner MediPharm announced a multifunctional label for GLP-1 pens and autoinjectors ahead of CPHI Milan 2026 that integrates UV protection and a temperature indicator [8].
What are the drivers, restraints, and opportunities in the pharmaceutical secondary packaging market?
In the pharmaceutical secondary packaging market, unit-level serialization enforcement and injectable GLP-1 pen launches are projected to expand converted carton orders whereas pulp and energy cost inflation restrains converter margins and smart NFC/RFID labels create high-value hospital authentication opportunities.
- Driver: Global enforcement of unit-level DSCSA and EU FMD serialization along with rising self-injected biologic volumes makes secondary cartons a required compliance layer.
- Restraint: High bleached paperboard and mill energy costs along with slow stability-filing reviews compress converter margins on fixed-price drug contracts.
- Opportunity: Paperboard vial cradles and sterilization-ready RFID inlays help converters win higher-margin biologic packaging contracts.
Growth Analysis and Future Potential: Qualitative Demand Catalysts
Counterfeit drug seizures and growing home use of injectable pens have turned outer cartons into active security components. According to the World Health Organization fact sheet on substandard and falsified medical products, low- and middle-income countries lose an estimated USD 30.5 billion each year to substandard and falsified medicines, while WHO and INTERPOL signed a stronger health-security agreement in October 2026 [9]. Drug manufacturers are therefore combining serialized cartons with smart connected packaging tags and void-release seals to protect oncology and metabolic medicines across international distribution.
Risk Assessment of the Pharmaceutical Secondary Packaging Market: Operational and Formulation Friction
Elevated bleached wood-pulp and chemical coating expenses paired with high mill energy input costs and rigid regulatory change-control protocols restrict margin expansion for secondary packaging converters. In August 2026, Graphic Packaging Holding Company reported second-quarter 2026 net sales of USD 2,188 million and Adjusted EBITDA of USD 247 million while implementing USD 85 million in structural cost actions to offset USD 150 million in expected full-year 2026 operating inflation [10]. When converters propose alternative board calipers or secondary cold-chain shippers, pharmaceutical quality assurance teams require six-to-twelve-month line trials that delay cost pass-through.
Commercial Opportunity Analysis: Formulation Differentiation and Value-Add Formats
Hospital pharmacies and biologic contract manufacturers favor converters that offer plastic-free paperboard vial trays and unit-level RFID tracking. Paperboard syringe cradles help drug brands meet European recycling rules whilst removing plastic thermoforming steps on the packing line. In March 2026, Avery Dennison Corporation launched its AD Minidose U9 Steri and AD Shelter Steri RFID inlays built to survive autoclave and ethylene-oxide sterilization on glass vials and syringes with over 99% read accuracy [11]. Converters that build sterilization-ready inlays into bio-medical packaging assemblies are expected to win multi-year hospital supply contracts.
Pharmaceutical Secondary Packaging Market by Country (2026 to 2036)
As per FMI, Brazil is projected to lead pharmaceutical secondary packaging market growth across major healthcare economies at a 5.9% CAGR through 2036, whereas Switzerland is forecast to progress at a 4.2% annual pace. Valuation differences between Latin American or Asian generic drug plants and established Western biologic hubs reflect local serialization deadlines and domestic carton converting capacity.
Table 7: Country CAGR and Primary Growth Levers for the Pharmaceutical Secondary Packaging Market (CAGR percentage and operational drivers), 2026 to 2036
| Country | CAGR (2026 to 2036) | Primary Growth Lever |
|---|---|---|
| Brazil | 5.9% | ANVISA SNCM 2D DataMatrix traceability and expanding domestic generic tablet carton output |
| South Korea | 5.7% | MFDS national biologics lot release growth and export-grade parenteral carton and label lines |
| USA | 4.6% | FDA DSCSA package-level EPCIS enforcement and GLP-1 autoinjector wallet and tray conversion |
| Germany | 4.3% | BfArM and EU FMD anti-tampering compliance paired with plastic-free paperboard vial trays |
| Switzerland | 4.2% | High-value exported biologics and Swissmedic packaging surveillance across Basel pharma hubs |
Source: Future Market Insights analysis
Brazil Pharmaceutical Secondary Packaging Market Outlook (2026 to 2036)
Brazil's pharmaceutical secondary packaging market is projected to expand at a leading 5.9% CAGR through 2036 as public-health generic tablet production rises across Sao Paulo and Goias industrial hubs. Under Federal Law 11.903/2009 and Law 13.410/2016 administered by the Brazilian Health Regulatory Agency (ANVISA), the National Medicine Control System (SNCM) uses two-dimensional DataMatrix barcodes to track prescription medicines across national distribution [12]. Domestic drug laboratories are therefore upgrading high-speed cartoning and laser-coding lines to keep pace with retail pharmacy volume. However, currency swings on imported bleached paperboard and humid transport routes require local converters to apply moisture-resistant barrier coatings so that prescription cartons hold their shape.
Key takeaway: In Brazil, ANVISA two-dimensional barcode tracking and expanding generic tablet volumes are projected to anchor market growth for moisture-resistant serialized folding cartons.
South Korea Pharmaceutical Secondary Packaging Market Outlook (2026 to 2036)
Large-scale contract biologics manufacturing in Songdo and Osong makes South Korea an export-intensive hub for parenteral vial trays and serialized secondary cartons. In June 2026, the Ministry of Food and Drug Safety (MFDS) published its 2025 Annual Report of National Lot Release detailing national lot release quality control across vaccines and plasma-derived biological products [13]. South Korean pharmaceutical secondary packaging market valuation is expected to climb at a 5.7% yearly rate over the 2026 to 2036 window as biosimilar exporters meet United States and European serialization rules. Even so, strict National Health Insurance drug reimbursement ceilings pressure domestic generic packagers to automate leaflet insertion and inline laser coding.
Key takeaway: In South Korea, MFDS biologics lot-release expansion and biosimilar export compliance are expected to accelerate market valuation for freeze-thaw-stable parenteral cartons.
USA Pharmaceutical Secondary Packaging Market Outlook (2026 to 2036)
Mandatory electronic interoperability under the Drug Supply Chain Security Act and surging domestic demand for self-administered metabolic pens set the United States apart from single-payer pharmaceutical markets. In August 2026, Amcor plc released its Fiscal 2026 Annual Report highlighting its first full year following the Berry Global acquisition with healthcare and wellness packaging representing roughly 25% of combined group portfolio activity [14]. United States pharmaceutical secondary packaging market size is anticipated to advance at a 4.6% annual clip through 2036 across contract packagers and hospital distribution networks. Because wholesalers quarantine shipments with unreadable barcodes, drug brands specify high-contrast clay-coated cartons and RFID-enabled unit labels across domestic finishing plants.
Key takeaway: In the USA, full FDA DSCSA enforcement and high-volume autoinjector launches are anticipated to sustain industry valuation across serialized cartons and RFID unit labels.
Germany Pharmaceutical Secondary Packaging Market Outlook (2026 to 2036)
German pharmaceutical secondary packaging market value is forecast to progress at a 4.3% CAGR through 2036 as drug plants in the Rhineland and Bavaria replace plastic vial trays with mono-material paperboard cradles. Under Germany's national verification system operated by securPharm e.V. and ACS PharmaProtect, prescription packs must carry a unique DataMatrix identifier and a DIN EN ISO 21976 anti-tampering device, while authorities gained access to the National Alert Management System from May 2025 [15]. Every pack anomaly triggers an electronic alert unless coding quality remains stable. High domestic power costs and statutory sickness-fund rebates therefore push German converters toward pre-glued carton sleeves and automated camera inspection.
Key takeaway: In Germany, securPharm verification rules and European circular packaging mandates are forecast to shift market value toward mono-material paperboard trays.
Switzerland Pharmaceutical Secondary Packaging Market Outlook (2026 to 2036)
Export-oriented oncology and immunology drug production centered in Basel and Visp makes Switzerland uniquely reliant on multi-language booklet labels and precision cold-chain folding cartons. On June 12, 2026, the Swiss Federal Council approved the 2025 Annual Report of Swissmedic confirming that the agency authorized 40 human medicinal products with new active substances and reduced median review turnaround times by 52 calendar days to 392 days [16]. Swiss pharmaceutical secondary packaging industry valuation is slated to grow at a 4.2% yearly pace through 2036 across Alpine finishing plants. Because Swiss finishers export to over 100 regulatory jurisdictions, converters must manage complex short-run artwork changes and zero-defect inline camera inspection.
Key takeaway: In Switzerland, rapid Swissmedic new-active-substance authorizations and global biologic exports are slated to support market size for short-run serialized cartons and booklet labels.
Full report country CAGRs cover: North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa.
Who are the notable companies in the pharmaceutical secondary packaging market?
Smurfit Westrock plc, Amcor plc, Graphic Packaging International, LLC, Mayr-Melnhof Karton AG, CCL Industries Inc., Korber Pharma Packaging, Schreiner Group GmbH & Co. KG, and Faller Packaging GmbH & Co. KG are the notable companies in the pharmaceutical secondary packaging market.
Suppliers in the pharmaceutical secondary packaging market fall into integrated paperboard groups along with healthcare label and cartoning specialists. Integrated board producers supply virgin and recycled cartonboard along with high-volume printed folding cartons for tablet lines. Specialized healthcare converters focus on child-resistant wallet packs and pre-inserted leaflets as well as sterilization-ready RFID vial labels where technical qualification matters more than raw board tonnage.
- Integrated Paperboard & Healthcare Carton Groups: Smurfit Westrock plc and Graphic Packaging International, LLC along with Mayr-Melnhof Karton AG and Amcor plc operate cartonboard mills and GMP folding-carton plants.
- Specialty Pharma Labeling & Smart-Tagging Converters: CCL Industries Inc. and Schreiner Group GmbH & Co. KG manufacture multi-page booklet labels and tamper-evident seals along with UHF/NFC RFID vial and autoinjector labels.
- Dedicated Pharma Secondary Packaging & Line Specialists: Korber Pharma Packaging and Faller Packaging GmbH & Co. KG supply paperboard syringe trays, Combi Pack carton-leaflet units, and integrated cartoning systems.
Competitive Benchmarking: Pharmaceutical Secondary Packaging Market
Table 8: Competitive Benchmarking for the Pharmaceutical Secondary Packaging Market (qualitative capability ratings), 2026
| Company | Secondary Carton Breadth | Serialization & RFID Depth | Cold-Chain & Biologic Fit | Geographic Reach |
|---|---|---|---|---|
| Smurfit Westrock plc | High | High | High | High |
| Amcor plc | High | Medium | High | High |
| Graphic Packaging International, LLC | High | Medium | High | High |
| Mayr-Melnhof Karton AG | High | Medium | Medium | High |
| CCL Industries Inc. | Medium | High | High | High |
| Korber Pharma Packaging | High | High | High | Medium |
| Schreiner Group GmbH & Co. KG | Medium | High | High | Medium |
| Faller Packaging GmbH & Co. KG | High | Medium | High | Medium |
Scoring basis: Capability tiers reflect documented GMP secondary carton and label breadth across oral solid and parenteral formats as well as GS1 2D DataMatrix and RFID/NFC integration depth. Cold-chain fit and geographic ratings reflect verified wet-strength board converting and multi-region clinical and commercial plant networks.
Key Developments in the Pharmaceutical Secondary Packaging Market
- Faller Packaging GmbH & Co. KG acquired Greek pharmaceutical folding-carton and leaflet specialist Paperpack in August 2026 to expand its European secondary healthcare packaging footprint [17].
- CCL Industries Inc. completed the acquisition of Sleever International in June 2026 after reporting record 2026 second-quarter financial results across its global label and healthcare packaging divisions in August 2026 [18].
- Mayr-Melnhof Karton AG published its 2025 Annual Results in March 2026 detailing specialized MM Packaging Pharma & Healthcare folding carton and security label operations across European and Americas plants [19].
Key Players in the Pharmaceutical Secondary Packaging Market
Integrated Paperboard & Healthcare Carton Groups
- Smurfit Westrock plc
- Amcor plc
- Graphic Packaging International, LLC
- Mayr-Melnhof Karton AG
Specialty Pharma Labeling & Smart-Tagging Converters
- CCL Industries Inc.
- Schreiner Group GmbH & Co. KG
Dedicated Pharma Secondary Packaging & Line Specialists
- Korber Pharma Packaging
- Faller Packaging GmbH & Co. KG
Pharmaceutical Secondary Packaging Market - Report Scope
Table 9: Report Scope for the Pharmaceutical Secondary Packaging Market (coverage fields and definitions), 2026 to 2036
| Coverage field | Report scope |
|---|---|
| Market breakdown | Secondary Format; Material; Therapeutic Class; Anti-Counterfeiting & Traceability; Cold-Chain Compatibility; Region |
| Quantitative Units | USD Billion |
| Market Definition | Includes commercial market value from exterior and intermediate pharmaceutical secondary packaging components including serialized folding cartons, wallet packs, tamper-evident labels, patient inserts and outserts, injector and vial protective trays, and shrink-wrapped multipack bundles. Category Scope Note: Excludes direct drug-contact primary containers (glass vials, ampoules, prefilled syringe barrels, and primary blister forming/lidding films) and bulk tertiary wooden/plastic shipping pallets. |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa |
| Countries Covered | Brazil, South Korea, USA, Germany, Switzerland, and additional countries in the full report |
| Key Companies Covered | Smurfit Westrock plc, Amcor plc, Graphic Packaging International, LLC, Mayr-Melnhof Karton AG, CCL Industries Inc., Korber Pharma Packaging, Schreiner Group GmbH & Co. KG, Faller Packaging GmbH & Co. KG |
| Forecast Period | 2026 to 2036 |
| Approach | Primary and secondary research with top-down and bottom-up market triangulation. |
Pharmaceutical Secondary Packaging Market - Research Methodology
Table 10: Research Methodology for the Pharmaceutical Secondary Packaging Market (research methods and approach), 2026 edition
| Method | Approach |
|---|---|
| Primary Research | Structured interviews with pharmaceutical packaging engineering directors, contract packaging organizations, serialization line integrators, and GMP folding-carton converters to validate per-pack realizations and qualification timelines. |
| Secondary Research | Analysis of corporate annual filings (10-K and IFRS reports), FDA DSCSA and EMA Falsified Medicines Directive compliance guidance, ANVISA SNCM and MFDS lot-release publications, and Swissmedic regulatory reports. |
| Market Sizing and Forecasting | Top-down pharmaceutical secondary packaging valuation models reconciled against bottom-up converted carton, wallet, label, and tray volumes across oral solid and parenteral drug classes from 2026 to 2036. |
| Country Forecasting Model | Econometric country projections weight national generic and biologic production volumes, statutory 2D barcode and EPCIS enforcement schedules, and domestic GMP carton converting capacity across five national healthcare markets. |
| Operational Benchmark Traceability | Converted pack volume and facility valuation indicators in Tables 2, 3, and 4 trace to FDA, EMA, WHO, MFDS, Swissmedic, and corporate packaging disclosures. |
| Data Triangulation and Validation | Market value estimates are cross-checked against commercial cartonboard tonnage and pharmaceutical label output without double counting direct-contact primary glass or blister containers. |
Pharmaceutical Secondary Packaging Market by Segments
Pharmaceutical Secondary Packaging Market segmented by Secondary Format:
- Serialized Folding Cartons & Wallet Packs
- Tamper-Evident Labels, Inserts & Outserts
- Injector & Vial Protective Trays
- Shrink-Wrapped Multipack Bundles
Pharmaceutical Secondary Packaging Market segmented by Material:
- Solid Bleached & Recycled Paperboard
- Thermoformed rPET/PP & Barrier Films
Pharmaceutical Secondary Packaging Market segmented by Therapeutic Class:
- Oral Solid Dose Blister & Bottle Cartons
- Parenteral Biologics, Pens & Prefilled Syringes
Pharmaceutical Secondary Packaging Market segmented by Anti-Counterfeiting & Traceability:
- 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals
- RFID / NFC Smart Unit-Level Tagging
- Holographic Foil, Microtext & Overt Ink
Pharmaceutical Secondary Packaging Market segmented by Cold-Chain Compatibility:
- Ambient Controlled Room Temperature
- Freeze-Thaw & 2°C to 8°C Wet-Strength Board
Pharmaceutical Secondary Packaging Market by Region
- North America
- United States
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Chile
- Western Europe
- Germany
- Switzerland
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Nordics
- Eastern Europe
- Poland
- Czech Republic
- Romania
- Hungary
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia and New Zealand
- Middle East and Africa
- GCC Countries
- South Africa
- Turkiye
- Israel
Research Sources and Bibliography
- [1] U.S. Food and Drug Administration (FDA). (2025, October 16). Drug Supply Chain Security Act (DSCSA) | FDA. U.S. Food and Drug Administration.
- [2] European Medicines Agency (EMA). (2026, January 15). Falsified medicines: overview | European Medicines Agency (EMA). European Medicines Agency.
- [3] Korber AG. (2026, May 07). Pharma inspection and packaging innovations at interpack 2026. Korber AG Newsroom.
- [4] Faller Packaging GmbH & Co. KG. (2026, April 01). Trade Press - Faller Packaging. Faller Packaging.
- [5] Stora Enso Oyj. (2025, March 19). Stora Enso's new consumer board line at the Oulu site in Finland has started operations. Stora Enso Newsroom.
- [6] Smurfit Westrock plc. (2025, November 04). Smurfit Westrock unveils world's first dedicated clinical packaging facility. Smurfit Westrock Newsroom.
- [7] Schreiner Group GmbH & Co. KG. (2026, May 05). RFID Labeling for Vials at interpack | Schreiner Group. Schreiner MediPharm.
- [8] Schreiner Group GmbH & Co. KG. (2026, September 24). Smart and Secure Labeling for GLP-1 Applications - Schreiner Group. Schreiner MediPharm.
- [9] World Health Organization (WHO). (2026, October 16). Substandard and falsified medical products. World Health Organization.
- [10] Graphic Packaging Holding Company. (2026, August 04). Graphic Packaging Holding Company Reports Second Quarter 2026 Financial Results :: Graphic Packaging Holding Company (GPK). Graphic Packaging Investor Relations.
- [11] Avery Dennison Corporation. (2026, March 27). Avery Dennison launches advanced RFID inlays compatible with major sterilization methods | Avery Dennison | RFID. Avery Dennison RFID.
- [12] Agencia Nacional de Vigilancia Sanitaria (ANVISA). (2026, May 17). Rastreabilidade - Portal Gov.br. Ministerio da Saude / Gov.br.
- [13] Ministry of Food and Drug Safety (MFDS). (2026, June 24). Ministry of Food and Drug Safety>Our Works>Bio&Cosmetics>Regulations>Biological Products / Herbal Medicines / Quasi-Drugs> View Details | Ministry of Food and Drug Safety. Ministry of Food and Drug Safety Republic of Korea.
- [14] Amcor plc. (2026, August 12). Amcor Annual Report FY26 | Amcor. Amcor Investor Relations.
- [15] securPharm e.V. (2025, November 06). Pharmaunternehmen - securPharm e.V. securPharm e.V. German Medicines Verification Organization.
- [16] Swissmedic. (2026, June 12). Swissmedic publishes its Annual Report and financial statements for 2025. Swiss Agency for Therapeutic Products.
- [17] Faller Packaging GmbH & Co. KG. (2026, August 13). Faller Packaging acquires Paperpack in Greece. Faller Packaging Corporate Press.
- [18] CCL Industries Inc. (2026, August 12). CCL Industries Announces Record Results for 2026 Second Quarter. CCL Industries Investor Relations.
- [19] Mayr-Melnhof Karton AG. (2026, March 17). MM reports Annual Results 2025. MM Group Investor Relations.
- [20] Korber AG. (2025, May 27). DSCSA Enforcement has begun - Korber. Korber Supply Chain Insights.
- [21] Amcor plc. (2026, August 12). Amcor reports strong fourth quarter and full-year results | Amcor. Amcor Media Newsroom.
This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.
This Report Answers
- How large is the pharmaceutical secondary packaging market in 2026 and what is forecast for 2036?
- Which serialization and cold-chain pressures support demand for pharmaceutical secondary packaging?
- Why do Serialized Folding Cartons & Wallet Packs lead the secondary format category?
- Why does Solid Bleached & Recycled Paperboard lead the material category globally?
- How do growth rates differ across Brazil, South Korea, the USA, Germany, and Switzerland?
- Which leading companies manufacture serialized pharmaceutical cartons, labels, and trays today?
- What limits adoption or supplier switching in the pharmaceutical secondary packaging market?
- What should pharmaceutical procurement teams evaluate before qualifying a secondary packaging converter?
Table of Content
Table of Content
- Key Takeaways
- Market Size and CAGR
- Top Growth Driver
- Fastest Growing Segment
- Leading Region
- Key Companies
- Emerging Opportunities
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Analyst Perspective (What is happening? Why now? What should investors know?)
- Key Questions Answered
- How large is the market?
- What is the CAGR?
- What are key trends?
- Which region dominates?
- Who are the leaders?
Read More...
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Expert Input and Fieldwork (Primary Evidence)
- Tooling, Models, and Reference Databases
- Data Engineering and Model Build
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics (Drivers, Restraints, Opportunity, Trends)
- Scenario Forecast (Optimistic, Likely, Conservative)
- Impact Analysis
- AI Impact
- Sustainability Impact
- Regulatory Impact
- Technology Impact
- Consumer / Buyer Analysis
- Purchase Drivers
- Adoption Barriers
- Buyer Journey
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter's Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Global Market Analysis and Forecast, 2021 to 2036
- Historical Market Size Value (USD Billion) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Billion) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis, 2021 to 2036
- Global Market Analysis and Forecast, By Secondary Format, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Billion) Analysis By Secondary Format, 2021 to 2025
- Current and Future Market Size Value (USD Billion) Analysis and Forecast By Secondary Format, 2026 to 2036
- Serialized Folding Cartons & Wallet Packs
- Tamper-Evident Labels, Inserts & Outserts
- Injector & Vial Protective Trays
- Shrink-Wrapped Multipack Bundles
- Y-o-Y Growth Trend Analysis By Secondary Format, 2021 to 2025
- Absolute $ Opportunity Analysis By Secondary Format, 2026 to 2036
- Global Market Analysis and Forecast, By Material, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Billion) Analysis By Material, 2021 to 2025
- Current and Future Market Size Value (USD Billion) Analysis and Forecast By Material, 2026 to 2036
- Solid Bleached & Recycled Paperboard
- Thermoformed rPET/PP & Barrier Films
- Y-o-Y Growth Trend Analysis By Material, 2021 to 2025
- Absolute $ Opportunity Analysis By Material, 2026 to 2036
- Global Market Analysis and Forecast, By Therapeutic Class, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Billion) Analysis By Therapeutic Class, 2021 to 2025
- Current and Future Market Size Value (USD Billion) Analysis and Forecast By Therapeutic Class, 2026 to 2036
- Oral Solid Dose Blister & Bottle Cartons
- Parenteral Biologics, Pens & Prefilled Syringes
- Y-o-Y Growth Trend Analysis By Therapeutic Class, 2021 to 2025
- Absolute $ Opportunity Analysis By Therapeutic Class, 2026 to 2036
- Global Market Analysis and Forecast, By Anti-Counterfeiting & Traceability, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Billion) Analysis By Anti-Counterfeiting & Traceability, 2021 to 2025
- Current and Future Market Size Value (USD Billion) Analysis and Forecast By Anti-Counterfeiting & Traceability, 2026 to 2036
- 2D DataMatrix GS1 Serialization & Tamper-Evident Glue/Seals
- RFID / NFC Smart Unit-Level Tagging
- Holographic Foil, Microtext & Overt Ink
- Y-o-Y Growth Trend Analysis By Anti-Counterfeiting & Traceability, 2021 to 2025
- Absolute $ Opportunity Analysis By Anti-Counterfeiting & Traceability, 2026 to 2036
- Global Market Analysis and Forecast, By Cold-Chain Compatibility, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Billion) Analysis By Cold-Chain Compatibility, 2021 to 2025
- Current and Future Market Size Value (USD Billion) Analysis and Forecast By Cold-Chain Compatibility, 2026 to 2036
- Ambient Controlled Room Temperature
- Freeze-Thaw & 2°C to 8°C Wet-Strength Board
- Y-o-Y Growth Trend Analysis By Cold-Chain Compatibility, 2021 to 2025
- Absolute $ Opportunity Analysis By Cold-Chain Compatibility, 2026 to 2036
- Global Market Analysis and Forecast, By Region, 2021 to 2036
- Introduction
- Historical Market Size Value (USD Billion) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Billion) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis and Forecast, By Country, 2021 to 2036
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- United States
- Canada
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- Latin America Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Mexico
- Argentina
- Chile
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- Western Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- Switzerland
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Nordics
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- Eastern Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Poland
- Czech Republic
- Romania
- Hungary
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- East Asia Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- South Asia and Pacific Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia and New Zealand
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- Middle East and Africa Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Billion) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Billion) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- GCC Countries
- South Africa
- Turkiye
- Israel
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- By Country
- Market Attractiveness Analysis
- By Country
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Key Takeaways
- Key Countries Market Analysis
- United States
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- United Kingdom
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Australia and New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Switzerland
- Pricing Analysis
- Market Share Analysis, 2025
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- United States
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Secondary Format
- By Material
- By Therapeutic Class
- By Anti-Counterfeiting & Traceability
- By Cold-Chain Compatibility
- Emerging Startups
- Innovation Benchmarking
- Competition Analysis
- Competition Deep Dive
- Smurfit Westrock plc
- Overview
- Product Portfolio
- Profitability by Market Segments
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Amcor plc
- Graphic Packaging International, LLC
- Mayr-Melnhof Karton AG
- CCL Industries Inc.
- Korber Pharma Packaging
- Schreiner Group GmbH & Co. KG
- Faller Packaging GmbH & Co. KG
- Smurfit Westrock plc
- Case Studies
- Success Stories
- Recent Developments
- Competition Deep Dive
- Assumptions & Acronyms Used
List of Tables
- Table 1: Global Market Value (USD Billion) Forecast by Region, 2021 to 2036
- Table 2: Global Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 3: Global Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 4: Global Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 5: Global Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 6: Global Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 7: North America Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 8: North America Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 9: North America Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 10: North America Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 11: North America Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 12: North America Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 13: Latin America Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 14: Latin America Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 15: Latin America Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 16: Latin America Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 17: Latin America Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 18: Latin America Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 19: Western Europe Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 20: Western Europe Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 21: Western Europe Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 22: Western Europe Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 23: Western Europe Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 24: Western Europe Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 25: Eastern Europe Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 26: Eastern Europe Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 27: Eastern Europe Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 28: Eastern Europe Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 29: Eastern Europe Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 30: Eastern Europe Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 31: East Asia Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 32: East Asia Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 33: East Asia Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 34: East Asia Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 35: East Asia Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 36: East Asia Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 37: South Asia and Pacific Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 38: South Asia and Pacific Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 39: South Asia and Pacific Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 40: South Asia and Pacific Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 41: South Asia and Pacific Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 42: South Asia and Pacific Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
- Table 43: Middle East and Africa Market Value (USD Billion) Forecast by Country, 2021 to 2036
- Table 44: Middle East and Africa Market Value (USD Billion) Forecast by Secondary Format, 2021 to 2036
- Table 45: Middle East and Africa Market Value (USD Billion) Forecast by Material, 2021 to 2036
- Table 46: Middle East and Africa Market Value (USD Billion) Forecast by Therapeutic Class, 2021 to 2036
- Table 47: Middle East and Africa Market Value (USD Billion) Forecast by Anti-Counterfeiting & Traceability, 2021 to 2036
- Table 48: Middle East and Africa Market Value (USD Billion) Forecast by Cold-Chain Compatibility, 2021 to 2036
List of Figures
- Figure 1: Global Market Pricing Analysis
- Figure 2: Global Market Value (USD Billion) Forecast 2021-2036
- Figure 3: Global Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 4: Global Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 5: Global Market Attractiveness Analysis by Secondary Format
- Figure 6: Global Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 7: Global Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 8: Global Market Attractiveness Analysis by Material
- Figure 9: Global Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 10: Global Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 11: Global Market Attractiveness Analysis by Therapeutic Class
- Figure 12: Global Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 13: Global Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 14: Global Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 15: Global Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 16: Global Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 17: Global Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 18: Global Market Value (USD Billion) Share and BPS Analysis by Region, 2026 and 2036
- Figure 19: Global Market Y-o-Y Growth Comparison by Region, 2026-2036
- Figure 20: Global Market Attractiveness Analysis by Region
- Figure 21: North America Market Incremental Dollar Opportunity, 2026-2036
- Figure 22: Latin America Market Incremental Dollar Opportunity, 2026-2036
- Figure 23: Western Europe Market Incremental Dollar Opportunity, 2026-2036
- Figure 24: Eastern Europe Market Incremental Dollar Opportunity, 2026-2036
- Figure 25: East Asia Market Incremental Dollar Opportunity, 2026-2036
- Figure 26: South Asia and Pacific Market Incremental Dollar Opportunity, 2026-2036
- Figure 27: Middle East and Africa Market Incremental Dollar Opportunity, 2026-2036
- Figure 28: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 29: North America Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 30: North America Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 31: North America Market Attractiveness Analysis by Secondary Format
- Figure 32: North America Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 33: North America Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 34: North America Market Attractiveness Analysis by Material
- Figure 35: North America Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 36: North America Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 37: North America Market Attractiveness Analysis by Therapeutic Class
- Figure 38: North America Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 39: North America Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 40: North America Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 41: North America Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 42: North America Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 43: North America Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 44: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 45: Latin America Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 46: Latin America Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 47: Latin America Market Attractiveness Analysis by Secondary Format
- Figure 48: Latin America Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 49: Latin America Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 50: Latin America Market Attractiveness Analysis by Material
- Figure 51: Latin America Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 52: Latin America Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 53: Latin America Market Attractiveness Analysis by Therapeutic Class
- Figure 54: Latin America Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 55: Latin America Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 56: Latin America Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 57: Latin America Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 58: Latin America Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 59: Latin America Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 60: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 61: Western Europe Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 62: Western Europe Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 63: Western Europe Market Attractiveness Analysis by Secondary Format
- Figure 64: Western Europe Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 65: Western Europe Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 66: Western Europe Market Attractiveness Analysis by Material
- Figure 67: Western Europe Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 68: Western Europe Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 69: Western Europe Market Attractiveness Analysis by Therapeutic Class
- Figure 70: Western Europe Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 71: Western Europe Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 72: Western Europe Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 73: Western Europe Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 74: Western Europe Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 75: Western Europe Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 76: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 77: Eastern Europe Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 78: Eastern Europe Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 79: Eastern Europe Market Attractiveness Analysis by Secondary Format
- Figure 80: Eastern Europe Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 81: Eastern Europe Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 82: Eastern Europe Market Attractiveness Analysis by Material
- Figure 83: Eastern Europe Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 84: Eastern Europe Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 85: Eastern Europe Market Attractiveness Analysis by Therapeutic Class
- Figure 86: Eastern Europe Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 87: Eastern Europe Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 88: Eastern Europe Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 89: Eastern Europe Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 90: Eastern Europe Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 91: Eastern Europe Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 92: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 93: East Asia Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 94: East Asia Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 95: East Asia Market Attractiveness Analysis by Secondary Format
- Figure 96: East Asia Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 97: East Asia Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 98: East Asia Market Attractiveness Analysis by Material
- Figure 99: East Asia Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 100: East Asia Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 101: East Asia Market Attractiveness Analysis by Therapeutic Class
- Figure 102: East Asia Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 103: East Asia Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 104: East Asia Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 105: East Asia Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 106: East Asia Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 107: East Asia Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 108: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 109: South Asia and Pacific Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 110: South Asia and Pacific Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 111: South Asia and Pacific Market Attractiveness Analysis by Secondary Format
- Figure 112: South Asia and Pacific Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 113: South Asia and Pacific Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 114: South Asia and Pacific Market Attractiveness Analysis by Material
- Figure 115: South Asia and Pacific Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 116: South Asia and Pacific Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 117: South Asia and Pacific Market Attractiveness Analysis by Therapeutic Class
- Figure 118: South Asia and Pacific Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 119: South Asia and Pacific Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 120: South Asia and Pacific Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 121: South Asia and Pacific Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 122: South Asia and Pacific Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 123: South Asia and Pacific Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 124: Middle East and Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 125: Middle East and Africa Market Value Share and BPS Analysis by Secondary Format, 2026 and 2036
- Figure 126: Middle East and Africa Market Y-o-Y Growth Comparison by Secondary Format, 2026-2036
- Figure 127: Middle East and Africa Market Attractiveness Analysis by Secondary Format
- Figure 128: Middle East and Africa Market Value Share and BPS Analysis by Material, 2026 and 2036
- Figure 129: Middle East and Africa Market Y-o-Y Growth Comparison by Material, 2026-2036
- Figure 130: Middle East and Africa Market Attractiveness Analysis by Material
- Figure 131: Middle East and Africa Market Value Share and BPS Analysis by Therapeutic Class, 2026 and 2036
- Figure 132: Middle East and Africa Market Y-o-Y Growth Comparison by Therapeutic Class, 2026-2036
- Figure 133: Middle East and Africa Market Attractiveness Analysis by Therapeutic Class
- Figure 134: Middle East and Africa Market Value Share and BPS Analysis by Anti-Counterfeiting & Traceability, 2026 and 2036
- Figure 135: Middle East and Africa Market Y-o-Y Growth Comparison by Anti-Counterfeiting & Traceability, 2026-2036
- Figure 136: Middle East and Africa Market Attractiveness Analysis by Anti-Counterfeiting & Traceability
- Figure 137: Middle East and Africa Market Value Share and BPS Analysis by Cold-Chain Compatibility, 2026 and 2036
- Figure 138: Middle East and Africa Market Y-o-Y Growth Comparison by Cold-Chain Compatibility, 2026-2036
- Figure 139: Middle East and Africa Market Attractiveness Analysis by Cold-Chain Compatibility
- Figure 140: Global Market - Tier Structure Analysis
- Figure 141: Global Market - Company Share Analysis
Frequently Asked Questions
How big is the pharmaceutical secondary packaging market in 2026, and what is forecast for 2036?
According to FMI, global pharmaceutical secondary packaging market size is estimated to reach USD 91.9 billion in 2026 from USD 87.5 billion in 2025. Industry valuation is forecast to hit USD 149.7 billion by 2036 as drug makers scale serialized folding cartons and biologic pen trays.
What is the CAGR for the pharmaceutical secondary packaging market from 2026 to 2036?
Future Market Insights projects a 5.0% compound annual growth rate between 2026 and 2036, representing an anticipated USD 57.8 billion increase in annual market value across oral and parenteral drug packaging lines.
Which secondary format segment leads the pharmaceutical secondary packaging market?
Serialized Folding Cartons & Wallet Packs are projected to capture 32.9% of secondary format market value in 2026 because flat board panels run at up to 500 cartons per minute while carrying GS1 2D DataMatrix codes and Braille embossing.
Which material segment leads the pharmaceutical secondary packaging market?
Solid Bleached & Recycled Paperboard is estimated to secure 77.9% of the material category valuation in 2026 as pharmaceutical brands replace thermoformed plastic vial cradles with recyclable clay-coated fiberboard.
Which country has a notable growth outlook during the assessment period?
Brazil is projected to lead national market growth at a 5.9% CAGR through 2036, backed by ANVISA SNCM two-dimensional barcode tracking and expanding domestic generic tablet production.
Who are the key players in the market?
Smurfit Westrock plc, Amcor plc, Graphic Packaging International, LLC, Mayr-Melnhof Karton AG, CCL Industries Inc., Korber Pharma Packaging, Schreiner Group GmbH & Co. KG, and Faller Packaging GmbH & Co. KG lead commercial supply across global healthcare converting networks.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDF
